FLIPL Activators
The chemical class of FLIPL activators comprises a diverse set of compounds with the ability to modulate the activity of FLIPL, a crucial player in apoptosis regulation. Betulinic Acid, SMAC Mimetic (LCL161), ATRA (All-trans Retinoic Acid), JSH-23, GS-143 (STF-62247), Diethyl Maleate, SAHA (Vorinostat), 2-Methoxyestradiol, Resveratrol, Curcumin, Bay 11-7082, and Parthenolide have been identified as activators, each with unique mechanisms of action. These activators influence FLIPL directly or indirectly by targeting various signaling pathways. Betulinic Acid, JSH-23, Diethyl Maleate, 2-Methoxyestradiol, Resveratrol, Curcumin, Bay 11-7082, and Parthenolide indirectly activate FLIPL by modulating the NF-κB signaling pathway. They prevent IκB degradation, inhibiting NF-κB activation and influencing the transcription of NF-κB target genes, including FLIPL. SMAC Mimetic (LCL161) indirectly activates FLIPL by modulating apoptotic pathways, antagonizing IAPs and releasing caspases. ATRA indirectly activates FLIPL by modulating the retinoic acid signaling pathway, influencing the transcription of FLIPL.
GS-143 (STF-62247) indirectly activates FLIPL by modulating the Hippo signaling pathway. It inhibits the Hippo pathway effector YAP/TAZ, leading to altered transcriptional regulation of FLIPL and other genes. SAHA (Vorinostat) indirectly activates FLIPL by modulating the acetylation status of histones, influencing chromatin structure and transcriptional regulation of FLIPL.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LCL-161 | 1005342-46-0 | sc-507541 | 10 mg | $360.00 | ||
LCL161, a SMAC (Second Mitochondria-derived Activator of Caspases) mimetic, indirectly activates FLIPL by modulating apoptotic pathways. LCL161 antagonizes inhibitor of apoptosis proteins (IAPs), releasing caspases from inhibition. This influences FLIPL, as caspases can cleave FLIPL, altering its activity and promoting apoptosis. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
ATRA indirectly activates FLIPL by modulating the retinoic acid signaling pathway. ATRA binds to retinoic acid receptors (RARs), leading to the transcriptional regulation of target genes, including FLIPL. The upregulation of FLIPL expression can influence cellular processes associated with retinoic acid signaling. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
JSH-23 indirectly activates FLIPL by modulating the NF-κB signaling pathway. It inhibits the nuclear translocation of NF-κB, thereby influencing the transcription of NF-κB target genes, including FLIPL. JSH-23's impact on FLIPL highlights its involvement in NF-κB-mediated cellular processes and offers a tool for dissecting the regulatory mechanisms governing FLIPL expression and activity. | ||||||
Diethylmaleate | 141-05-9 | sc-202577 | 5 g | $27.00 | 4 | |
Diethyl Maleate indirectly activates FLIPL by modulating the NF-κB signaling pathway. It enhances the nuclear translocation of NF-κB, influencing the transcription of NF-κB target genes, including FLIPL. Diethyl Maleate's impact on FLIPL highlights its involvement in NF-κB-mediated cellular processes and provides a tool for studying the regulatory mechanisms governing FLIPL expression and activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
SAHA (Vorinostat), a histone deacetylase (HDAC) inhibitor, indirectly activates FLIPL by modulating the acetylation status of histones. HDAC inhibition increases histone acetylation, leading to altered chromatin structure and transcriptional regulation of FLIPL. SAHA's impact on FLIPL provides insights into the epigenetic regulation of FLIPL expression and its potential as a pharmacological tool for investigating FLIPL-associated pathways. | ||||||
2-Methoxyestradiol | 362-07-2 | sc-201371 sc-201371A | 10 mg 50 mg | $71.00 $288.00 | 6 | |
2-Methoxyestradiol indirectly activates FLIPL by modulating the NF-κB signaling pathway. It inhibits IκB degradation, preventing NF-κB activation and influencing the transcription of NF-κB target genes, including FLIPL. 2-Methoxyestradiol's impact on FLIPL highlights its involvement in NF-κB-mediated cellular processes and provides a tool for studying the regulatory mechanisms governing FLIPL expression and activity. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol indirectly activates FLIPL by modulating the NF-κB signaling pathway. It inhibits IκB degradation, preventing NF-κB activation and influencing the transcription of NF-κB target genes, including FLIPL. Resveratrol's impact on FLIPL provides insights into its role in NF-κB-mediated cellular processes and offers a tool for studying the regulatory mechanisms governing FLIPL expression and activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 indirectly activates FLIPL by modulating the NF-κB signaling pathway. It inhibits IκB degradation, preventing NF-κB activation and influencing the transcription of NF-κB target genes, including FLIPL. Bay 11-7082's impact on FLIPL provides insights into its role in NF-κB-mediated cellular processes and offers a tool for studying the regulatory mechanisms governing FLIPL expression and activity. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide indirectly activates FLIPL by modulating the NF-κB signaling pathway. It inhibits IκB degradation, preventing NF-κB activation and influencing the transcription of NF-κB target genes, including FLIPL. Parthenolide's impact on FLIPL highlights its involvement in NF-κB-mediated cellular processes and provides a tool for studying the regulatory mechanisms governing FLIPL expression and activity. | ||||||